Marita Ziepert

Summary

Affiliation: University of Leipzig
Country: Germany

Publications

  1. ncbi Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma
    M Ziepert
    Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
    Ann Oncol 19:752-62. 2008
  2. doi Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era
    Marita Ziepert
    Dipl Math, Institute for Medical Informatics, Statistics, and Epidemiology, Universitat Leipzig, Härtelstrasse 16 18, D 04107 Leipzig, Germany
    J Clin Oncol 28:2373-80. 2010
  3. doi Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma
    Gerhard Held
    Gerhard Held, Niels Murawski, Jochen Fleckenstein, Viola Pöschel, Carsten Zwick, Jörg Bittenbring, Jörg Schubert, Christian Rübe, and Michael Pfreundschuh, Universitatsklinikum des Saarlandes, Homburg Marita Ziepert and Markus Löffler, Universitat Leipzig, Leipzig Mathias Hänel, Klinikum Chemnitz, Chemnitz Sibylla Wilhelm, Stadtisches Klinikum Karlsruhe, Karlsruhe and Norbert Schmitz, Asklepios Klinik St Georg, Hamburg, Germany
    J Clin Oncol 32:1112-8. 2014
  4. doi Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab
    Jörg Thomas Bittenbring
    Jörg Thomas Bittenbring, Frank Neumann, Marina Achenbach, Jörg Reichrath, Jürgen Geisel, Evi Regitz, Gerhard Held, and Michael Pfreundschuh, Klinik fur Innere Medizin I, Universitatsklinikum des Saarlandes, Homburg and Bettina Altmann and Marita Ziepert, University Leipzig, Leipzig, Germany
    J Clin Oncol 32:3242-8. 2014
  5. doi Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens
    L Trumper
    Hematology and Oncology, University Hospital Gottingen, Germany
    Ann Oncol 19:538-44. 2008

Collaborators

Detail Information

Publications5

  1. ncbi Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma
    M Ziepert
    Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
    Ann Oncol 19:752-62. 2008
    ..Little is known on the heterogeneity of hematotoxicity in patients receiving multicycle chemotherapy...
  2. doi Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era
    Marita Ziepert
    Dipl Math, Institute for Medical Informatics, Statistics, and Epidemiology, Universitat Leipzig, Härtelstrasse 16 18, D 04107 Leipzig, Germany
    J Clin Oncol 28:2373-80. 2010
    ..To investigate whether the IPI has maintained its power for risk stratification when rituximab is combined with CHOP, we analyzed the prognostic relevance of IPI in three prospective clinical trials...
  3. doi Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma
    Gerhard Held
    Gerhard Held, Niels Murawski, Jochen Fleckenstein, Viola Pöschel, Carsten Zwick, Jörg Bittenbring, Jörg Schubert, Christian Rübe, and Michael Pfreundschuh, Universitatsklinikum des Saarlandes, Homburg Marita Ziepert and Markus Löffler, Universitat Leipzig, Leipzig Mathias Hänel, Klinikum Chemnitz, Chemnitz Sibylla Wilhelm, Stadtisches Klinikum Karlsruhe, Karlsruhe and Norbert Schmitz, Asklepios Klinik St Georg, Hamburg, Germany
    J Clin Oncol 32:1112-8. 2014
    ..A prospective trial was conducted to investigate the role of additive radiotherapy (RT) to bulky and extralymphatic disease...
  4. doi Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab
    Jörg Thomas Bittenbring
    Jörg Thomas Bittenbring, Frank Neumann, Marina Achenbach, Jörg Reichrath, Jürgen Geisel, Evi Regitz, Gerhard Held, and Michael Pfreundschuh, Klinik fur Innere Medizin I, Universitatsklinikum des Saarlandes, Homburg and Bettina Altmann and Marita Ziepert, University Leipzig, Leipzig, Germany
    J Clin Oncol 32:3242-8. 2014
    ..To investigate the impact and mechanisms of vitamin D deficiency (VDD) on the outcome of elderly patients with diffuse large B-cell lymphoma (DLBCL)...
  5. doi Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens
    L Trumper
    Hematology and Oncology, University Hospital Gottingen, Germany
    Ann Oncol 19:538-44. 2008
    ..To determine the maximum tolerated dose of a bi- and tri-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone plus etoposide (CHOEP) regimen without stem-cell support...